tenofovir disoproxil fumarate + emtricitabine + maraviroc

This is a combination drug containing **tenofovir disoproxil fumarate**, **emtricitabine**, and **maraviroc**, developed primarily for the prevention and treatment of HIV infections. - **Tenofovir disoproxil fumarate** is a nucleotide analog reverse transcriptase inhibitor (NtRTI) that acts as a chain terminator, inhibiting HIV-1 viral replication by competing with natural deoxyadenosine 5′-triphosphate for incorporation into viral DNA[4][2]. - **Emtricitabine** is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits viral replication via incorporation into viral DNA, causing chain termination[2]. - **Maraviroc** is a CCR5 receptor antagonist that blocks the entry of HIV-1 into human cells by preventing its interaction with the CCR5 cell surface receptor[3]. This drug combination represents a synergistic approach to HIV therapy: tenofovir disoproxil fumarate and emtricitabine disrupt viral replication, while maraviroc prevents virus internalization. The drug has been investigated in formulations such as intravaginal rings for HIV prevention[3]. Primary indication: **HIV prevention**, including pre-exposure prophylaxis (PrEP) and prevention of sexual transmission of HIV.

Other names

emtricitabine/maraviroc/tenofovir disoproxil fumarate intravaginal ring